In a study, 3 women aged 23-35 years were identified, who acquired K103N mutilation during treatment with lamivudine/ zidovudine, emtricitabine/tenofovir, efavirenz and/or nevirapine for HIV-1 infections leading to treatment failure.
The women, who had a history of HIV-1 infection, were started on efavirenz and lamivudine/zidovudine (patient 1), nevirapine and emtricitabine/tenofovir (patient 2), and efavirenz and emtricitabine/tenofovir (patient 3) [dosages and routes not stated]. They developed isolated K103N mutation that led to virological failure. At the time of virological failure, tests showed HIV-1 RNA 34300copies/mL in patient 1 and > 100000 copies/mL in patients 2 and 3.
The women's treatments were switched to rilpivirine/ emtricitabine/tenofovir and 12 weeks later, tests showed HIV-1 RNA of < 50 copies/mL in all patients.
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